Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher A. Kroeger
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 133
- Beta
- 2.57
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 10.00
Financials
MPLT has only 11 quarterly periods on file — the charts below show the full history available.
Net Income
$-60.19MEBITDA
$-63.40MFree Cash Flow
$-44.89MEPS (diluted)
$-1.32Shares Outstanding (diluted)
45.43M+9.7%Operating Expenses
$63.40MCash & Debt
$304.73MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-161.15M | $-3.66 |
| 2024 | $0.00 | $-77.58M | $-1.87 |
| 2023 | $0.00 | $-55.71M | $-1.34 |
| 2022 | $0.00 | $-30.02M | $-0.72 |
Valuation
MPLThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-25.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Negative
…nce and helped inspire MapLight's circuit-based approach to drug discovery SAN FRANCISCO and BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics (Nasdaq: MPLT) celebrates Karl Deisseroth, M.D., Ph.D., co-founder and Scientific Advisory Board member of MapLight, who was awarded the 2026 Nobel Prize in Physiology or Medicine.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
MapLight Therapeutics to Participate in Upcoming Investor Conference SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:
View source ↗ - Newsglobenewswire.com·54d ago·Negative
…ight Therapeutics Announces $150 Million Private Placement Financing SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE…
View source ↗
Earnings
Thu, Dec 3(in 8 weeks)
Consensus estimate $-1.18 per share
Typical surprise -18.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Sep 18$-1.32 vs $-1.35beat
- Thu, Aug 13$-1.32 vs $-1.35beat
- Fri, May 15$-1.34 vs $-1.05miss
- Thu, Dec 4$-37.18 vs $-1.72miss
- Fri, Aug 22$-1.14 vs $-0.96miss
Estimates and results for MPLT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in MPLT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.